MissionIR News - BioDelivery Sciences (BDSI) and Endo Pharmaceuticals (ENDP) Ink $180M Licensing and Development Agreement

Share Article

Endo Pharmaceuticals to be responsible for the manufacturing, distribution, marketing and sales of BEMA Buprenorphine on a worldwide basis.

The addition of BEMA Buprenorphine will broaden Endo’s portfolio of pain therapeutics, allowing us to offer an integrated suite of products that currently includes Opana ER, Voltaren Gel and Lidoderm, as well as a broad range of generic pain products.

MissionIR would like to highlight BioDelivery Sciences International, Inc., a publicly traded specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. The company is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.

In the company’s news yesterday,

BioDelivery Sciences International announced it has signed a $180 million agreement with Endo Pharmaceuticals for worldwide exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

BEMA Buprenorphine utilizes BioDelivery Sciences’ patented BioErodible MucoAdhesive (BEMA) technology to deliver the pain-reliving opiate drug.

Per the agreement, Endo will be responsible for the manufacturing, distribution, marketing and sales of BEMA Buprenorphine on a worldwide scale. Both companies will collaborate to organize the phase III clinical development program and regulatory strategy for BEMA Buprenorphine for chronic pain.

BioDelivery Sciences will be responsible for the conduct of planned clinical studies leading up to the submission of the New Drug Application (NDA), and Endo will pick up from there with the responsibility of submitting the NDA and managing the interactions with FDA.

The agreement is worth up to $180 million to BioDelivery Sciences if all milestones are met. Financial terms of the agreement include an upfront payment of $30 million; $95 million in commercial milestone payments based on achievement of pre-defined intellectual property, clinical development and regulatory events; $55 million in potential sales milestones upon achievement of designated sales levels; and a tiered mid to upper teen royalty on U.S. net sales of BEMA Buprenorphine.

Dr. Mark A. Sirgo, president and CEO of BioDelivery Sciences, praised Endo’s financial strength, market presence and focus in pain management.

Dave Holveck, president and CEO of Endo, noted BEMA Buprenorphine’s value to Endo’s product portfolio.

“Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain,” Holveck stated in the press release. “The addition of BEMA Buprenorphine will broaden Endo’s portfolio of pain therapeutics, allowing us to offer an integrated suite of products that currently includes Opana ER, Voltaren Gel and Lidoderm, as well as a broad range of generic pain products. We look forward to working closely with BDSI on the development of this important asset.”

About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com.

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR.

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR.

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

MissionIR Communications
Visit website